EIC funding to develop SN132D - the first selective contrast agent for MRI diagnostics of endometriosis
| Reference number | |
| Coordinator | Spago Nanomedical AB (publ) |
| Funding from Vinnova | SEK 300 000 |
| Project duration | January 2024 - June 2024 |
| Status | Completed |
| Venture | Preparation projects for international application within health |
| Call | Preparation project for international proposal in health and food 2023 |
Important results from the project
The project aim was to prepare a competitive proposal for EIC Accelerator, including market analysis, application texts, financial model and mandatory appendices, such as pitch deck and annex. During the course of the project, we have prepared and submitted a stage 1 and a full stage 2 proposal to EIC Accelerator.
Expected long term effects
The project aim has been fulfilled as we completed the preparations that were planned and submitted a stage 1 and step 2 application.
Approach and implementation
During the preparation phase, we have carried out a detailed market analysis, drawn up a regulatory plan and created and submitted proposal to EIC Accelerator. The project has been carried out according to plan.